Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 68788-7459

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 68788-7459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rabeprazole Sodium Delayed Released Tablets 20mg (Rabe 30 Count)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg by Preferred Pharmaceuticals, Inc. The label indicates generic for Aciphex with each tablet containing 20 mg rabeprazole sodium. It includes storage instructions, warnings, manufacturer Ascend Laboratories, LLC, and dosage directions in English and Spanish on a yellow background. Barcode and QR code are visible.*

FDA Label Image

Rabe-str (Rabe Str)

Chemical structure diagram of the active ingredient Rabeprazole Sodium, showing its molecular components including sulfur, nitrogen, oxygen, and sodium atoms arranged in a specific configuration.*

FDA Label Image

Rabe-str2 (Rabe Str2)

A line chart depicts mean heartburn scores over 28 study days comparing placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The y-axis shows mean score severity from 0 (none) to 4 (very severe). Scores for Rabeprazole groups decrease more than placebo after day 0.*

FDA Label Image

Rabe-str3 (Rabe Str3)

A line graph comparing mean heartburn scores over a 28-day study period between a placebo group (n=58) and a Rabeprazole Sodium 20 mg group (n=59). The x-axis represents study days, ranging from -14 to 28, and the y-axis represents mean heartburn scores from 0 (None) to 4 (Very Severe). Scores decrease notably after day 0 in the Rabeprazole group compared to placebo.*

FDA Label Image

Rabe-str4 (Rabe Str4)

A line graph comparing mean heartburn scores over a 28-day study period between placebo and Rabeprazole Sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows heartburn severity scores from 0 (none) to 4 (very severe). The graph indicates a decrease in heartburn scores for both groups after day 0, with the Rabeprazole group generally showing lower scores than placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.